Determination of the International Sensitivity Index of a New Near-Patient Testing Device to Monitor Oral Anticoagulant Therapy

Summary

A key issue for the reliable use of new devices for the laboratory control of oral anticoagulant therapy with the INR is their conformity to the calibration model. In the past, their adequacy has mostly been assessed empirically without reference to the calibration model and the use of International Reference Preparations (IRP) for thromboplastin. In this study we reviewed the requirements to be fulfilled and applied them to the calibration of a new near-patient testing device (TAS, Cardiovascular Diagnostics) which uses thromboplastin-containing test cards for determination of the INR. On each of 10 working days citrat- ed whole blood and plasma samples were obtained from 2 healthy subjects and 6 patients on oral anticoagulants. PT testing on whole blood and plasma was done with the TAS and parallel testing for plasma by the manual technique with the IRP CRM 149S. Conformity to the calibration model was judged satisfactory if the following requirements were met: (i) there was a linear relationship between paired log-PTs (TAS vs CRM 149S); (ii) the regression line drawn through patients data points, passed through those of normals; (iii) the precision of the calibration expressed as the CV of the slope was <3%. A good linear relationship was observed for calibration plots for plasma and whole blood (r = 0.98). Regression lines drawn through patients data points, passed through those of normals. The CVs of the slope were in both cases 2.2% and the ISIs were 0.965 and 1.000 for whole blood and plasma. In conclusion, our study shows that near-patient testing devices can be considered reliable tools to measure INR in patients on oral anticoagulants and provides guidelines for their evaluation.

• References

• 1 Lucas FV, Duncan A, Jay R, Coleman R, Craft P, Chan B, Winfrey L, Mungall DR, Hirsh J. A novel whole blood capillary technique for measuring the prothrombin time. Am J Clin Path 1987; 88: 442-446
• 2 Ansell J, Holden A, Knapic RN. Patient self-management of oral anticoagulation guided by a capillary (fingerstick) whole blood prothrombin times. Arch Int Med 1989; 149: 2509-2511
• 3 Jennings I, Luddington RJ, Baglin T. Evaluation of the Ciba Coming Biotrack 512 coagulation monitor for the control of anticoagulation. J Clin Path 1991; 44: 950-953
• 4 Weibert RT, Adler DS. Evaluation of a capillary whole-blood prothrombin time measurement system. Clin Pharm 1989; 8: 864-867
• 5 White RH, Me CurdySA, von MarensdorffH, Woodruff Jr DE, Leftgoff L. Home prothrombin time monitoring after initiation of warfarin therapy. Ann Int Med 1989; 111: 730-737
• 6 Tripodi A, Arbini AA, Chantarangkul V, Bettega D, Mannucci PM. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the International Normalized Ratio. Thromb Haemost 1993; 70: 921-924
• 7 van den BesselaarAMHP, Breddin K, Lutze G, Parker-Williams J, Taborski U, Vogel G, Tritschler W, Zerback R, Leinberger R. Multicenter evaluation of a new capillary blood prothrombin time monitoring system. Blood Coag Fibr 1995; 6: 726-732
• 8 WHO Expert Committee on Biological Standardization. Thirty-third Report. Technical Report Series 687. WHO; Geneva: 1983
• 9 World Health Organization. Recommended methodology for using WHO International Reference Preparations for thromboplastins. Available from WHO, 1211 Geneva 27, Switzerland
• 10 Tomenson JA. A statistician’s independent evaluation. In: Thromboplastin calibration and oral anticoagulant control. van den BesselaarAMHP, Gralnick HR, Lewis SM. (eds). Boston: Martinus Nijhoff Publishers; 1984. pp 87-108
• 11 Kirkwood TBL. Calibration of reference thromboplastins and standardization of the prothrombin time. Thromb Haemost 1983; 49: 238-244
• 12 Hermans J, van den BesselaarAMHP, Loeliger EA, van derVelde EA. A collaborative calibration study of reference materials for thromboplastins. Thromb Haemost 1983; 50: 712-717
• 13 Thomson JM, Tomenson JA, Poller L. The calibration of the Second Primary International Reference Preparation for thromboplastin (Thromboplastin human, plain, coded BCT/253). Thromb Haemost 1984; 52: 336-342
• 14 Thomson JM, Darby KV, Poller L. Calibration of BCT/441, the ICSH Reference Preparation for thromboplastin. Thromb Haemost 1986; 55: 379-382
• 15 van den BesselaarAMHP, Bertina RM. Multi-center calibration of the Second Reference Material for thromboplastin, Rabbit, Plain, coded CRM 149R. Thromb Haemost 1991; 65: 263-267
• 16 van den BesselaarAMHP. Multicenter study of replacement of the International Reference Preparation for thromboplastin, Rabbit, Plain. Thromb Haemost 1993; 70: 794-799
• 17 Tripodi A, Chantarangkul V, Braga M, Poller L, ten CateJW, van den BesselaarAMHP, Mannucci PM. Results of a multicenter study assessing the status of standardization of a recombinant thromboplastin for the control of oral anticoagulant therapy. Thromb Haemost 1994; 72: 261-267
• 18 van den BesselaarAMHP. Multicenter calibration of the third BCR Reference Material for thromboplastin, rabbit, plain, coded CRM 149S. Longterm stability of previous BCR reference materials. Thromb Haemost 1995; 74: 1465-1467
• 19 van derVelde EA. Orthogonal regression equation. In: Thromboplastin calibration and oral anticoagulant control. van den BesselaarAMHP, Gralnick HR, Lewis SM. (eds). Boston: Martinus Nijhoff Publishers; 1984. pp 25-39
• 20 Gogstad GO, Wadt J, Smith P, Brynildsrud T. Utility of a modified calibration model for reliable conversion of thromboplastin times to international normalized ratios. Thromb Haemost 1986; 56: 178-182
• 21 van den BesselaarAMHP, Bertina RM. Multicenter study of thromboplastin calibration. Precision-Influence of reagent species, composition, and international sensitivity index (ISI). Thromb Haemost 1993; 69: 35-40
• 22 Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1995; 108 (Suppl): 231-245